Adderall Improves Life for Those With ADHD
Posted on: Thursday, 22 May 2003, 06:00 CDT
Study finds long-term use helps children and adults with attention disorder
HealthScoutNews -- The quality of life for children with attention-deficit/hyperactivity disorder (ADHD) improves with long-term use of a once-daily stimulant called Adderall XR.
The results of this, the largest ADHD clinical trial to date, were presented May 21 at the American Psychiatric Association annual meeting in San Francisco.
The seven-week, open-label study included 2,900 children previously treated with a stable dose of ADHD medication, either methylphenidate HC1 or another methylphenidate product or a mixed salts amphetamine product.
After they were switched to once-daily Adderall XR, the children showed better symptom management and significant improvement in their quality of life as measured on the 23-item Pediatric Quality of Life Inventory, the study says.
"This largest study ever of ADHD patients establishes the significant improvements that treatment with the once-daily mixed salts amphetamine medication brings in decreasing symptoms. Such symptom control allows children to functionally improve and participate in life, such as engage in sports, get along with other kids, or help with chores," lead investigator Dr. Paul J. Ambrosini, a professor of psychiatry at Drexel University College of Medicine in Philadelphia, says in a news release.
In a separate study, researchers at the University of North Carolina at Chapel Hill found adults with ADHD treated long-term with an extended-release mixed-salts amphetamine medication maintained significant symptom improvement.
The study of 248 adults with ADHD was also presented May 21 at the American Psychiatric Association annual meeting.
"ADHD is not just a childhood disorder. While hyperactivity may sometimes diminish by adulthood, inattention and impulsivity often remain," researcher Dr. Richard Weisler, adjunct professor of psychiatry, says in a news release.
"Our findings suggest that, as in children with ADHD, adults who have this condition can benefit from treatment with this product. This medication can significantly improve adults' ADHD symptoms and, subsequently, their ability to work, socialize and be more productive in everyday activities," Weisler says.
-----
On the Net:
More science, space, and technology from RedNova
Copyright © 2003 HealthScoutNews. All rights reserved. The information contained above is intended for general reference purposes only. It is not a substitute for professional medical advice or a medical exam. Always seek the advice of your physician or other qualified health professional before starting any new treatment. Medical information changes rapidly and while Yahoo and its content providers make efforts to update the content on the site, some information may be out of date. No health information on Yahoo, including information about herbal therapies and other dietary supplements, is regulated or evaluated by the Food and Drug Administration and therefore the information should not be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor.
Related Articles
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
- Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
- Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
- New Study Finds That Most Common Registry Cleaner Software Products Do More Harm Than Good
- FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
- Montecito Medical Acquires Medical Office Building
- Study Suggests Strattera(R) Was Effective in Treating ADHD in Children and Adolescents With ADHD and Reading Disorders
- Mixed Amphetamine Salts Most Effective in the Treatment of ADHD in Youths Reports the SUNY Upstate Medical Center
- Cephalon Receives Approvable Letter for SPARLON(TM) for the Treatment of ADHD in Children and Adolescents
- Research and Markets: India's Pharmaceutical, Life Sciences and Medical Equipment Markets in the Throes of Rapid Modernization
 |
 |
User Comments (0)
RSS Feeds